Author: Rico-Mesa, Juan Simon; Rosas, Daniel; Ahmadian-Tehrani, Ashkan; White, Averi; Anderson, Allen S.; Chilton, Robert
Title: The Role of Anticoagulation in COVID-19-Induced Hypercoagulability Cord-id: krfo7zky Document date: 2020_6_17
ID: krfo7zky
Snippet: PURPOSE OF REVIEW: We aim to provide a comprehensive analysis of hypercoagulability in individuals affected by COVID-19. Our goal is to describe the hypercoagulable state related to the infection and provide guidance regarding the possible benefits of anti-coagulation with the support of evidence from current literature. RECENT FINDINGS: The incidence of thrombotic disease in individuals affected by COVID-19 is reported as high as 31%. A significant mortality benefit has been observed with the u
Document: PURPOSE OF REVIEW: We aim to provide a comprehensive analysis of hypercoagulability in individuals affected by COVID-19. Our goal is to describe the hypercoagulable state related to the infection and provide guidance regarding the possible benefits of anti-coagulation with the support of evidence from current literature. RECENT FINDINGS: The incidence of thrombotic disease in individuals affected by COVID-19 is reported as high as 31%. A significant mortality benefit has been observed with the use of therapeutic anticoagulation in high-risk individuals. Literature supports the use of scoring systems, such as the sepsis-induced coagulopathy score, to risk-stratify individuals who might benefit from anticoagulation. SUMMARY: COVID-19-induced hypercoagulability has been demonstrated to play a significant role in overall COVID-19 outcomes. Current literature shows promising evidence with the use of therapeutic anticoagulation in high-risk individuals. Further studies are needed to better analyze the risks and benefits of anticoagulation in this specific patient population.
Search related documents:
Co phrase search for related documents- acute phase protein and lung damage: 1, 2
- acute phase protein and lung tissue: 1
- acute phase protein and macrophage activation: 1
- acute phase protein and macrophage activation syndrome: 1
- acute severe pneumonia and adjunctive treatment: 1
- acute severe pneumonia and low molecular: 1, 2, 3
- acute severe pneumonia and low molecular weight heparin: 1, 2, 3
- acute severe pneumonia and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute severe pneumonia and lung present: 1, 2, 3
- acute severe pneumonia and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute severe pneumonia and lung tissue damage: 1, 2, 3, 4
- acute severe pneumonia and macrophage activation: 1
- acute severe pneumonia and macrophage activation syndrome: 1
- adjunctive treatment and lmwh adjunctive treatment: 1
- adjunctive treatment and lmwh weight heparin: 1
- adjunctive treatment and low molecular: 1
- adjunctive treatment and low molecular weight heparin: 1
- adjunctive treatment and lung damage: 1, 2, 3, 4
- adjunctive treatment and lung present: 1
Co phrase search for related documents, hyperlinks ordered by date